Responses to Ponatinib at early landmark time points are associated with Progression-Free Survival (PFS) and Overall Survival (OS) in heavily pretreated Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) patients (Pts)
ONCOLOGY RESEARCH AND TREATMENT（2015）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要